Canaccord raised the firm’s price target on Omada Health (OMDA) to $28 from $27 and keeps a Buy rating on the shares. The firm noted they reported their first quarter as a public company and said they were pleasantly surprised with the magnitude of the upside, with member and revenue growth surpassing our estimates by 6.7% and 11.5%, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health price target raised to $24 from $21 at Barclays
- Omada Health, Inc.: Strong Market Position and Growth Potential Justify Buy Rating
- Omada Health Reports Strong Q2 2025 Growth
- Omada Health sees FY25 revenue $235M-$241M, consensus $221.84M
- Omada Health reports Q2 EPS (24c), consensus (13c)